Fundz

Who to call at Novo Nordisk, and when

Fundz watches for the moments Novo Nordisk starts buying, and tells you who to reach.

  • An alert the day Novo Nordisk raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Novo Nordisk, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Novo Nordisk. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Novo Nordisk, Valo Health Announce Expanded $4.6B AI Partnership

Jan 08, 2025

Contract Type

partnership

DenmarkManufacturingScience And Engineering

Description

Novo Nordisk and Valo Health have expanded their collaboration into an up-to-$4.6 billion-plus artificial intelligence partnership aimed at discovering and developing up to 20 treatments for obesity, type 2 diabetes, and cardiovascular disease. The partnership will combine Novo Nordisk’s expertise in cardiometabolic diseases with Valo’s Opal Computational Platform™ to glean insights from human genetic and longitudinal patient data.

Quick answer

Novo Nordisk, Valo Health Announce Expanded $4.6B AI Partnership (January 8, 2025). Novo Nordisk is based in Denmark.

What agreement did Novo Nordisk announce on January 8, 2025?
Novo Nordisk and Valo Health have expanded their collaboration into an up-to-$4.6 billion-plus artificial intelligence partnership aimed at discovering and developing up to 20 treatments for obesity, type 2 diabetes, and cardiovascular disease. The partnership will combine Novo Nordisk’s expertise in cardiometabolic diseases with Valo’s Opal Computational Platform™ to glean insights from human genetic and...
What does Novo Nordisk do?
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
Where is Novo Nordisk based?
Novo Nordisk is based in Denmark.

Source: Fundz verified event record.

Company Information

Company

Novo Nordisk

Location

Denmark

About

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries.

Related People

Jacob
Likely contact at this company
••••••••@••••••••

See Jacob's verified email →

Karsten
Likely contact at this company
••••••••@••••••••

See Karsten's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Novo Nordisk's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Novo Nordisk signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.